A family office with USA offices has a focus on the social impact as an overall investment mandate. The firm aims to fund cutting-edge therapeutics companies, through their accelerator arm while also investing in later-stage assets. The firm will invest globally. For their accelerator arm, the firm is seeking companies with pre-clinical and clinical therapeutics with a minimum initial investment of $1M-$10M, with the possibility of follow-on investments. The firm generally invests in companies with lead assets in Phase I – III clinical trials, and the amount of the allocation is based on the raise and pre-money valuation of the company.

The firm is looking for therapeutics companies, with a particular interest in biologics assets such as antibody-based technologies, cell and gene therapies. The firm mandate focused on regenerative and personalized medicine in oncology, neurodegenerative, orphan, and rare disease applications.

The firm will only consider companies that have more than two assets in the pipeline and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech sector fund with headquarters in China is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. The firm works with top ten largest global pharmaceutical companies and small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Medical Devices Healthcare IT companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.

The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.

The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A UAE registered investment consultancy firm’s core activities involve independent advisory, outsourced CIO, and direct investments. The firm acts as the consultant role to advise global family offices with their investment objectives. The firm looking for investment leads in early-stage life science industry. Companies who are looking to raise their series B – series C rounds would be the sweet spot. The firm typically invests in $5M-25M, which depends on the stage of development. The firm is also open to looking at earlier stage companies but the investment size might vary. The firm is looking for companies in the US (60%), China (20%), UK, Germany, India, and other countries with emerging life science technologies.

The firm is opportunistic in sectors and is willing to consider any indications.

The firm has no specific requirements for companies. The firm might take an observer seat or board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is interested in a broad range of technology companies, including those in the software, cloud services, IT, and Internet sectors. In the life sciences, the firm will only invest in the healthcare IT sector. The firm invests in late seed to early Series A rounds with a typical investment size ranges from $50,000 to $2M. Investment is typically in form of equity, though convertible loan and other capital structures would be considered as well. The firm will look at investment opportunities across the US with a focus on West Coast.

The firm will make new investments in the healthcare IT sector. The firm is interested in healthcare services and IT companies targeting platform, enterprise software, m-health, solution, data analytics and consumer health. The firm will invest in commercial-stage companies with products or services on the market.

The firm invests in privately held healthcare companies. The firm focuses on companies with annual revenues of between $0.5M and $10M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the USA focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $500K-$1M, and the firm has made one investment so far. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities. The firm also has interests in other technology fields. The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $100M of annual revenues.

The firm seeks a reliable and experienced management team that can bring the concept to market. The firm may take a board seat in applicable cases. The firm aims fundraising CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.